These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 6437113)

  • 1. Effect of ascorbic acid on desferrioxamine-induced urinary iron excretion in idiopathic hemochromatosis.
    Conte D; Brunelli L; Ferrario L; Mandelli C; Quatrini M; Velio P; Bianchi PA
    Acta Haematol; 1984; 72(2):117-20. PubMed ID: 6437113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of ascorbic acid deficiency on desferrioxamine-induced urinary iron excretion.
    Wapnick AA; Lynch SR; Charlton RW; Seftel HC; Bothwell TH
    Br J Haematol; 1969 Dec; 17(6):563-8. PubMed ID: 5357744
    [No Abstract]   [Full Text] [Related]  

  • 3. Ascorbic acid status in idiopathic hemochromatosis.
    Brissot P; Deugnier Y; Le Treut A; Regnouard F; Simon M; Bourel M
    Digestion; 1978; 17(6):479-87. PubMed ID: 710734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Further experiences with iron-chelating therapy (desferrioxamine and ascorbic acid) in siderochromatosis and Cooley's disease].
    Cartei G; Cazzavillan M; Chisesi T; Battista R; Barbui T; Dini E
    Minerva Med; 1978 Mar; 69(13):811-21. PubMed ID: 643223
    [No Abstract]   [Full Text] [Related]  

  • 5. Continuous intravenous deferoxamine infusion. Treatment of secondary hemochromatosis in adults.
    Blume KG; Beutler E; Chillar RK; Fahey JL; Sharkoff D; Zia PK
    JAMA; 1978 May; 239(20):2149-51. PubMed ID: 642157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of subcutaneous deferoxamine and oral vitamin C on iron excretion in congenital hypoplastic anemia and refractory anemia associated with the 5q-syndrome.
    Ambruso DR; Mahony BS; Githens JH; Rhoades ED
    Am J Pediatr Hematol Oncol; 1982; 4(2):115-23. PubMed ID: 7114394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Four-hour measurement of urinary iron excretion after deferoxine treatment: a rapid, simple method for study of iron excretion.
    Bonkovsky HL; Weber R; Aaron L
    Am J Gastroenterol; 1990 May; 85(5):554-7. PubMed ID: 2337058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of dose, time, and ascorbate on iron excretion after subcutaneous desferrioxamine.
    Hussain MA; Green N; Flynn DM; Hoffbrand AV
    Lancet; 1977 May; 1(8019):977-9. PubMed ID: 67469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of phenylhydrazine-induced haemolysis on the urinary excretion of iron after desferrioxamine.
    Cumming RL; Goldberg A; Morrow J; Smith JA
    Lancet; 1967 Jan; 1(7481):71-4. PubMed ID: 4163055
    [No Abstract]   [Full Text] [Related]  

  • 10. [Post-desferrioxamine urinary iron in iron-overload states].
    Santiago Corchado M; Ribas Ozonas B
    Rev Clin Esp; 1970 Jul; 118(2):151-8. PubMed ID: 5486372
    [No Abstract]   [Full Text] [Related]  

  • 11. Ascorbic acid enhancement of desferrioxamine-induced urinary iron excretion in thalassemia major.
    O'Brien RT
    Ann N Y Acad Sci; 1974; 232(0):221-5. PubMed ID: 4528431
    [No Abstract]   [Full Text] [Related]  

  • 12. [Effect of desferrioxamine B and 2-(beta-aminoethoxy)cyclohexylaminetetraacetate in experimental hemochromatosis in rats and in primary hemochromatosis of man].
    Bohne F; Lessmann J
    Arzneimittelforschung; 1969 Jun; 19(6):944-7. PubMed ID: 5820039
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of ascorbic acid on desferrioxamine therapy.
    Cartei G; Meani A
    Acta Vitaminol Enzymol; 1970; 24(6):209-13. PubMed ID: 5537933
    [No Abstract]   [Full Text] [Related]  

  • 14. Excretion of iron in response to deferoxamine in sickle cell anemia.
    Cohen A; Schwartz E
    J Pediatr; 1978 Apr; 92(4):659-62. PubMed ID: 633013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Yersinia enterocolitica septicemia associated with idiopathic hemochromatosis and deferoxamine therapy. A case].
    Nouel O; Voisin PM; Vaucel J; Dartois-Hoguin M; Le Bris M
    Presse Med; 1991 Oct; 20(31):1494-6. PubMed ID: 1835044
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral ascorbic acid and iron excretion in thalassemic children treated with desferrioxamine-methansulfonate (Desferal).
    Hathirat P; Isarangkura P; Areekul S; Pleehachinda R; Tuntawiroon M
    Birth Defects Orig Artic Ser; 1988; 23(5B):129-33. PubMed ID: 3390535
    [No Abstract]   [Full Text] [Related]  

  • 17. Reassessment of the use of desferrioxamine B in iron overload.
    Propper RD; Shurin SB; Nathan DG
    N Engl J Med; 1976 Jun; 294(26):1421-3. PubMed ID: 1272274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New diagnostic and therapeutic possibilities in manifest idiopathic hemochromatosis.
    Volkholz HJ; Sailer D; Rödl W
    Hepatogastroenterology; 1984 Dec; 31(6):289-94. PubMed ID: 6519641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vitamin C, desferrioxamine and iron loading anemias.
    Van der Weyden MB
    Aust N Z J Med; 1984 Oct; 14(5):593-5. PubMed ID: 6597704
    [No Abstract]   [Full Text] [Related]  

  • 20. A comparison of desferrioxamine-induced sideruria and measurement of labile iron store as indices of body iron status.
    Singh AK
    J Med; 1971; 2(6):345-62. PubMed ID: 5292126
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.